DailyIQ
Last updatedUpdating…

ZTS·Zoetis Inc.

$71.55
+0.22 (+0.31%)
After Hours
High
$72.09
Open
$71.73
Market Cap
29.71B
52W High
$148.30
Low
$71.03
P. Close
$71.55
P/E
11.36
52W Low
$68.77
Fwd P/E
10.99
DailyIQ Est.
$99.32
Inst. Ownership
42.8%
Short Interest
4.19%
Days to Cover
3.8
Technical Score (1D)
18
BEARISH
News Sentiment
51
MIXED
On Oct 6, Zoetis released the transcript of its second‑quarter 2026 earnings call. The transcript detailed the company’s financial performance for the period, including revenue, earnings per share, and guidance. Management noted that the results did not deviate materially from expectations. No significant events or catalysts were highlighted in the discussion. The disclosure provides investors with a comprehensive view of the company’s quarterly performance.
LOW TARGET
$80 +11.8%
3 analysts
MEAN TARGET
$96 +34.2%
10 analysts
HIGH TARGET
$155 +116.6%
13 analysts
PRICE RANGE
$80.00 - $155.00
SB / B / H / S / SS
4/8/12/1/1
DAILYIQ EST.
$99.32 (+38.8%)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYQ
Country
United States
Website
Symbol
ZTS
Description
Zoetis Inc. is a global leader in animal health, focused on developing and delivering a comprehensive portfolio of medicines, vaccines, diagnostic products, and services for both livestock and companion animals. The company's core value proposition lies in its broad product offerings, spanning parasiticides, vaccines, and diagnostics, catering to a diverse range of species including cattle, swine, poultry, dogs, and cats. Zoetis commercializes its products through various channels, targeting veterinarians, livestock producers, and pet owners. This expansive reach, combined with its commitment to innovation, including a collaboration for novel antibiotic development, positions Zoetis as a key player in the growing animal health market. Founded in 1950, the company is headquartered in Parsippany, New Jersey.
Bought (1Y)
0 shares
$0
Sold (1Y)
274 shares
$19K
FULLER JULIEExecutive Vice President
Option Exercise799.071 shares2026-09-30
FULLER JULIEExecutive Vice President
Tax Withholding274 shares2026-09-30
FULLER JULIEExecutive Vice President
Option Exercise799 shares2026-09-30
Stetter Mark-
Award/Grant342.372 shares2026-09-17
SACCARO JAMESEVP, CFO & COO
Award/Grant81,063 shares2026-08-31
75/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
28.2%
Revenue CAGR
5.9%
Current Ratio
3.03x
Debt / Equity
2.71x
Return on Equity
80.2%
Earnings Summary
Zoetis Inc. is a global leader in animal health, offering a broad portfolio of medicines, vaccines, diagnostics, and services for livestock and companion animals, operating within the specialty drug manufacturing sector. The company’s extensive product range and global sales network position it as a key player in the growing animal health market. In the most recent quarters, Zoetis reported EPS of $1.48 in Q4 2025 and $1.53 in Q1 2026, both slightly below analyst expectations of $1.616 and $1.615, respectively, while revenue rose to $2.387 billion in Q1 2026 from $2.387 billion in Q4 2025, reflecting a modest 3.66% decline versus the prior year’s $2.387 billion estimate. The company’s EPS trend shows a slight acceleration from $1.4 in Q4 2024 to $1.76 in Q2 2025, followed by a dip to $1.7 in Q3 2025 and a modest decline to $1.48 in Q4 2025, indicating volatility but generally positive momentum. Historically, Zoetis has maintained a YoY revenue growth trajectory, with revenue increasing from $2.317 billion in Q4 2024 to $2.467 billion in Q2 2026, while EPS has fluctuated around analyst estimates, often beating in Q2 2025 but missing in Q4 2025 and Q1 2026. This pattern suggests that revenue growth can persist even when EPS misses expectations, likely due to margin pressures or product mix shifts. Recent news highlights concerns about the durability of Zoetis’s competitive moat as patents expire, with analysts projecting a 10.59% decline in EPS to $1.52 and a 3.66% drop in revenue to $2.31 billion for the quarter ending November 5, 2026, potentially impacting investor sentiment.

EPS

EstBeatMiss
$1.42$1.55$1.68$1.81$1.93Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.51 - -
Q2'26$1.87$1.87-0.2%
Q1'26$1.62$1.53-5.3%
Q4'25$1.62$1.48-8.4%
Q3'25$1.62$1.70+4.8%
Q2'25$1.61$1.76+9.2%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.5B$2.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.3B - -
Q2'26$2.5B$2.5B-2.3%
Q1'26$2.3B$2.3B-2.8%
Q4'25$2.3B$2.4B+3.1%
Q3'25 - $2.4B -
Q2'25 - $2.5B -

Market Data

ZTS Stock Snapshot

BEARISH18/100
$71.55+$0.00 (0.0%)
Market cap
29.71B
P/E ratio
11.4
Day range
$71.03 – $72.09
News sentiment
51/100 · Neutral
Analyst target
$96.00 (+34.2%)
Consensus
Hold · 26 analysts
52-week range+4.0% off low · -51.8% from high
$68.77$148.30
Price $71.55 DailyIQ Est. $99.32

Price action on ZTS is defensive - rallies are being sold rather than extended. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Behaviour On Record

What ZTS's own history says about today's numbers

Realized volatility (21d)
19.2% 34th pct
Below its peak
-71.1%
vs 200-day average
-27.5%
Up days (1y)
46%

Zoetis Inc. is currently running 19.2% annualised volatility over the last 21 sessions. Measured against ZTS's own 13 years of daily returns rather than a market-wide average, that is the 34th percentile — on the quiet side for this stock, against a typical reading of 22.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ZTS is trading -71.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -19.6%, and the deepest was -43.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -27.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 3rd percentile — a narrower gap than it typically runs. Over the past year ZTS closed higher on 46% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, ZTS finished the month higher 4 of 13 times, with a median return of -1.6% and an average of -1.4%. Its strongest month historically has been July at +3.7% on average, its weakest March at -2.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ZTS has opened more than 2% away from the prior close in 80 of 3,267 sessions (2.4% of the time), with the largest gaps running +7.7% and -6.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ZTS moved an average of 4.3% in the session after earnings, closing higher 1 of those 3 times, with a median move of -5.6% and a largest of -6.2%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ZTS's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ZTS's sector?

Zoetis Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64

Options Market

What is the options market pricing for ZTS?

CallsPuts

For Zoetis Inc.'s nearest expiry (2026-10-16, 9 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.10), with at-the-money implied volatility around 43.5%. The options market is pricing roughly a ±6.1% move by that expiry — a range of about $65.71–$74.27.

Put/call ratio (2026-10-16)
1.10
ATM implied volatility
43.5%
Total open interest
21,344
Expected move by 2026-10-16
±6.1% ($65.71–$74.27)

Analyst Rating Changes

Are analysts turning bullish or bearish on ZTS?

TD Cowen most recently reiterated its rating on Zoetis Inc. to Buy on Aug 25, 2026 with a price target of $94 (from $104). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
TD Cowen — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Aug 25, 2026TD CowenMaintainedBuy$104 → $94
Aug 20, 2026StifelMaintainedHold$85 → $80
Aug 11, 2026CitigroupMaintainedBuy$112 → $96
Aug 11, 2026BNP ParibasMaintainedOutperform$146 → $110
Aug 10, 2026Piper SandlerMaintainedNeutral$90 → $80
Aug 7, 2026UBSMaintainedNeutral$85 → $80
Aug 7, 2026JP MorganMaintainedOverweight$130 → $115
Aug 6, 2026William BlairDowngradeOutperform → Market Perform-
Jul 27, 2026UBSMaintainedNeutral$99 → $85
Jul 22, 2026Morgan StanleyMaintainedOverweight$115 → $99
Jul 6, 2026HSBCMaintainedBuy$140 → $95
Jul 1, 2026BarclaysMaintainedEqual-Weight$136 → $85

ZTS Competitive Positioning

Zoetis Inc. (ZTS) is tracked alongside these names in Drug Manufacturers - Specialty & Generic on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

51/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Zoetis released the transcript of its second‑quarter 2026 earnings call on October 6. The company discussed its financial performance for the period, including revenue, earnings per share, and guidance. No significant deviations from expectations or material events were highlighted in the transcript. The disclosure provides investors with detailed commentary from management but does not indicate any major upside or downside catalysts.
What did this article say?
Zoetis Inc. has long maintained a dominant position in animal health through a broad portfolio of medicines, vaccines, and diagnostics supported by a robust patent portfolio and strong veterinary relationships. However, analysts are questioning whether the company’s moat is beginning to erode as competitors intensify their focus on similar product categories and as key patents approach expiration. The company’s reliance on brand loyalty and quality may help sustain market share, but the potential loss of exclusivity could expose it to increased price competition. This uncertainty introduces a mild headwind to Zoetis’s future growth prospects.
What did this article say?
Zoetis (ZTS) closed at $69.10, down 1.05% on the day, following a broader market decline. The company’s upcoming earnings report, slated for November 5, 2026, is expected to show a 10.59% drop in EPS to $1.52 and a 3.66% decline in revenue to $2.31 billion for the quarter. Analysts note that the forecasted earnings and revenue shortfalls could weigh on investor sentiment and potentially impact the stock’s valuation. The negative outlook is compounded by a 8.32% monthly decline in shares, outpacing the broader medical sector. Overall, the market reaction reflects concerns over the company’s near‑term financial performance.
What did this article say?
Zoetis Inc. (ZTS) experienced a 71% decline in its share price, dropping from $244 in December 2021 to $71 by September 2023. The steep fall reflects investor concerns over the company’s margin strength and the looming risk of patent expirations for key products. Analysts highlighted that the current valuation of $113 per share is far below the market price, underscoring the perceived overvaluation. The decline signals a significant loss of investor confidence and may prompt a reassessment of the company’s growth prospects.
What did this article say?
Zoetis (ZTS) was evaluated as a solid value investment on September 25. Analysts highlighted its low price-to-earnings ratio, robust 9/10 profitability rating, and solid return on invested capital. The company maintains a sustainable dividend policy, though growth prospects and leverage levels were noted as potential risks. The assessment suggests a mildly positive outlook for the stock without indicating any immediate material upside.
What did this article say?
Zoetis (ZTS) closed at $70.27 on September 24, falling 1.87% and lagging the broader market. The company’s upcoming earnings are expected to show a 10.59% decline in EPS to $1.52 and a 3.66% drop in quarterly revenue to $2.31 billion. Analysts anticipate a modest decline in full‑year earnings and revenue, with EPS projected at $6.20 and revenue at $9.24 billion, down 3.28% and 2.45% respectively. The market reaction reflects concerns over weaker profitability and potential downward revisions to analyst estimates.
What did this article say?
Zoetis Inc. scheduled a webcast and conference call for November 5, 2026, to present its third‑quarter 2026 financial results. The event will feature CEO Kristin Peck and CFO/COO Jay Saccaro, who will review performance metrics and answer analyst questions. Investors can access the live session and slide deck via the company’s investor website, with a replay available after the call. The announcement provides standard disclosure of upcoming earnings communication without indicating any material change in guidance or performance outlook.
What did this article say?
The companion animal diagnostics market is projected to grow from $3.56 billion in 2026 to $5.40 billion by 2031, an 8.7% CAGR. Growth is driven by rising pet healthcare spending, preventive care, chronic and infectious diseases, and advances in AI, molecular diagnostics, point‑of‑care testing and automated analyzers. Zoetis is highlighted as a key player in this expanding market, positioned to capture increased demand for diagnostics and related consumables. The forecast indicates a robust tailwind for Zoetis’s diagnostics business and potential revenue growth in the coming years.
What did this article say?
Michael Burry has increased his stake in Zoetis (ZTS) after a 50% decline, describing the company as "extremely out of favor" and lacking a COVID or AI catalyst. The move signals a value‑oriented bet rather than a growth play, reflecting Burry’s broader strategy of avoiding crowded AI stocks. The addition may attract attention from value investors but does not indicate a fundamental turnaround for ZTS.

Technical Analysis

Real-time indicators across multiple timeframes

18
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $15.26B combined position · 12 adding, 11 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy47,780,97411.51%$6.01B2026-01-29
BlackRock, Inc.▲ Buy39,430,1819.50%$2.83B2026-08-07
Geode Capital Management, LLC▲ Buy13,289,6223.20%$951.79M2026-08-12
Wellington Management Group LLP▼ Sell9,423,8952.27%$677.20M2026-08-14
Morgan Stanley▼ Sell8,878,8492.14%$638.03M2026-08-13
Janus Henderson Group plc• Hold3,701,7470.89%$437.57M2026-05-18
Northern Trust Corp▼ Sell5,542,2341.33%$398.26M2026-08-13
Invesco Ltd.▲ Buy5,523,0181.33%$396.88M2026-08-14
Citadel Advisors LLC• Hold5,210,9631.25%$374.46M2026-09-02
Norges Bank▼ Sell4,689,8471.13%$337.01M2026-08-12
Bank of America Corp▼ Sell3,924,9260.95%$282.05M2026-08-14
Goldman Sachs Group Inc▼ Sell3,736,0990.90%$268.48M2026-08-14
Susquehanna International Group, LLP▲ Buy3,367,2580.81%$241.97M2026-08-14
JPMorgan Chase & Co▼ Sell2,630,9250.63%$192.72M2026-08-12
Ruane, Cunniff & Goldfarb L.P.▼ Sell2,353,3000.57%$169.11M2026-08-14
Artisan Partners Limited Partnership▲ Buy1,004,2110.24%$146.94M2025-11-12
Millennium Management LLC▲ Buy2,008,4590.48%$144.33M2026-08-14
Wells Fargo & Company▼ Sell1,815,2780.44%$130.45M2026-08-14
Man Group plc▲ Buy1,805,0030.43%$129.71M2026-08-14
Citigroup Inc▲ Buy1,415,2100.34%$101.70M2026-08-03
Renaissance Technologies LLC▲ Buy1,403,3000.34%$100.84M2026-08-13
AllianceBernstein L.P.▼ Sell698,4520.17%$82.56M2026-08-14
AQR Capital Management LLC▲ Buy1,070,9290.26%$76.96M2026-08-14
Capital Research Global Investors▼ Sell980,8110.24%$70.48M2026-08-12
Squarepoint Ops LLC▲ Buy952,7700.23%$68.47M2026-08-14
Q2 2026 flow:13.36M sh bought ($959.76M)16.24M sh sold ($1.30B)net -2.88M sh (−$344.23M)
Congressional Trading Activity
25 disclosed trades · ~$322.5K est. traded value · 11 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-07-172026-09-04
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-162026-07-02
Byron DonaldsHouseFL19▲ Buy$1K - $15K2026-06-092026-07-15
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-04-142026-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-03-132026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-02-102026-03-09
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-192026-01-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Rick LarsenHouseWA02▼ Sell$1K - $15K2025-10-062025-10-16
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-072025-05-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-052025-04-11
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-03-032025-04-14
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-01-152025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2024-12-112025-08-13
Shelley Moore CapitoSenateWV▲ Buy$15K - $50K2024-02-272024-03-15
Dan SullivanSenateAK▼ Sell$1K - $15K2023-08-222023-09-22